1. <scp>MITF</scp> deficiency and oncogenic <scp>GNAQ</scp> each promote proliferation programs in zebrafish melanocyte lineage cells
- Author
-
Grace B. Phelps, Adam Amsterdam, Hannah R. Hagen, Nicole Zambrana García, and Jacqueline A. Lees
- Subjects
Uveal Neoplasms ,Microphthalmia-Associated Transcription Factor ,Oncogenes ,Dermatology ,General Biochemistry, Genetics and Molecular Biology ,Oncology ,Mutation ,Animals ,GTP-Binding Protein alpha Subunits, Gq-G11 ,Melanocytes ,Cell Lineage ,Melanoma ,Zebrafish ,Cell Proliferation - Abstract
Uveal melanoma (UM) is the most common primary malignancy of the adult eye but lacks any FDA-approved therapy for the deadly metastatic disease. Thus, there is a great need to dissect the driving mechanisms for UM and develop strategies to evaluate potential therapeutics. Using an autochthonous zebrafish model, we previously identified MITF, the master melanocyte transcription factor, as a tumor suppressor in GNAQsupQ209L/sup-driven UM. Here, we show that zebrafish mitfa-deficient GNAQsupQ209L/sup-driven tumors significantly up-regulate neural crest markers, and that higher expression of a melanoma-associated neural crest signature correlates with poor UM patient survival. We further determined how the mitfa-null state, as well as expression of GNAQsupQ209L/sup, YAPsupS127A;S381A/sup, or BRAFsupV600E/suponcogenes, impacts melanocyte lineage cells before they acquire the transformed state. Specifically, examination 5 days post-fertilization showed that mitfa-deficiency is sufficient to up-regulate pigment progenitor and neural crest markers, while GNAQsupQ209L/supexpression promotes a proliferative phenotype that is further enhanced by YAPsupS127A;S381A/supco-expression. Finally, we show that this oncogene-induced proliferative phenotype can be used to screen chemical inhibitors for their efficacy against the UM pathway. Overall, this study establishes that a neural crest signature correlates with poor UM survival, and describes an in vivo assay for preclinical trials of potential UM therapeutics.
- Published
- 2022
- Full Text
- View/download PDF